BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 18, 2010
View Archived Issues
Novel DNA-alkylating agents described by Syntarga
Read More
Novel PI3K inhibitors presented by Shionogi
Read More
Kowa describes novel JAK inhibitors
Read More
Merck & Co. claims new antihypertensive agents
Read More
Cardiolynx patents new nitrate esters of valsartan and cilostazol
Read More
Long-term pimavanserin safe and well tolerated in Parkinson's disease psychosis
Read More
Pramipexole ER shows long-term efficacy and safety in advanced Parkinson's disease
Read More
GIND and ISB join to identify genes and targets involved in Huntington's disease
Read More
Milatuzumab-doxorubicin conjugate enters phase I/II trial in MM
Read More
Catena demonstrates visual benefits in Leber's hereditary optic neuropathy
Read More
TX-RAD completes preclinical development for inflammatory arthritis
Read More
Final phase II data on voreloxin/cytarabine in AML support phase III testing
Read More
SRX-251 shows favorable safety, tolerability and pharmacokinetics in healthy subjects
Read More
AZD-6244 is beneficial in phase II trial in IRPTC and PTC
Read More
CEP cells show promise as biomarker for response to antiangiogenic therapy in CRPC
Read More
Abbott and Neurocrine join to develop elagolix for endometriosis
Read More
Safety monitoring board recommends continuation of phase III Allovectin-7 trial
Read More
Durect reports on phase IIb hysterectomy trial of Posidur
Read More
Akebia's HIF-PH inhibitor AKB-6548 effective in phase Ib trial
Read More
Phase IIa trial of NU-1618 in hyperuricemia meets primary endpoint
Read More
Phase II trial of GDC-0449 in colorectal cancer does not meet primary endpoint
Read More
EMD Serono resumes BLP-25 liposome vaccine program in lung cancer
Read More
OBI-1 obtains positive opinion for orphan drug status in Europe
Read More
OncoMed and Bayer Schering form anticancer stem cell alliance
Read More
Thallion closes phase II TLN-232 trial following arbitral tribunal decision
Read More
Relypsa begins phase II trial of RLY-5016 for hyperkalemia
Read More
FDA approves Jevtana for metastatic hormone-refractory prostate cancer
Read More